Atherosclerotic Cardiovascular Disease

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

Catch up on major trial results, groundbreaking guideline updates, and more.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.

Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

Bhatt shares his thoughts on the recently released dyslipidemia guidelines, highlighting the return of goal-based LDL-C therapy and Lp(a) receiving a COR 1 suggestion.

New dyslipidemia guidance sharpens risk with CAC, checks lipoprotein(a), and targets LDL goals using expanded therapies for prevention.

New dyslipidemia guidance sets LDL targets for FH, urges genetic testing, and highlights evinacumab and APOC3 drugs for severe triglycerides.

Trials show most heart supplements don’t lower LDL or prevent events; learn why omega‑3s, vitamins and red yeast rice fall short of statins.

New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.

New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.

New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.

New guidance shows how risk enhancers and coronary calcium scores refine statin decisions, including handling incidental CAC on routine CT scans.

New ACC/AHA lipid update explains PREVENT risk equations, updated thresholds, and when to start statins or CAC scoring to prevent heart attacks.

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

This conference preview with Kathryn Berlacher, MD, MS, and Kristen Campbell, PharmD, highlights the top 6 trials to watch at ACC 2026.

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.